To access the live webcasts of the presentation and breakout session, or the subsequent archived recordings, please visit the “Investors” section of the Ziopharm website at www.ziopharm.com.
BOSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2020, at 9:30 a.m. PT (12:30 p.m. ET).
To access the live webcasts of the presentation and breakout session, or the subsequent archived recordings, please visit the “Investors” section of the Ziopharm website at www.ziopharm.com.
About Ziopharm Oncology, Inc.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral Sleeping Beauty platform for T-cell receptor (TCR) and chimeric antigen receptor (CAR) T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express TCRs to target neoantigens inside and outside hotspots for solid tumors and CAR to target CD19 for blood cancers using the Company’s “Rapid Personalized Manufacture” to produce and release CAR-T as soon as the day after gene transfer. The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company is also developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Contacts for Ziopharm Oncology:
Chris Taylor
VP, Investor Relations and Corporate Communications
T: 617-502-1881
E: ctaylor@ziopharm.com
Lisa M. Wilson
In-Site Communications, Inc.
E: lwilson@insitecony.com
